Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lessened its stake in Myriad Genetics, Inc. (NASDAQ:MYGN) by 3.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 109,216 shares of the company’s stock after selling 3,815 shares during the period. Thrivent Financial for Lutherans’ holdings in Myriad Genetics were worth $2,992,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in MYGN. State of New Jersey Common Pension Fund D purchased a new stake in shares of Myriad Genetics in the 3rd quarter valued at about $1,965,000. Legato Capital Management LLC purchased a new position in shares of Myriad Genetics during the second quarter worth approximately $1,123,000. Assenagon Asset Management S.A. increased its holdings in shares of Myriad Genetics by 26.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 250,524 shares of the company’s stock valued at $6,128,000 after acquiring an additional 52,813 shares during the period. Maven Securities LTD purchased a new stake in Myriad Genetics in the 2nd quarter valued at $1,223,000. Finally, Tidal Investments LLC acquired a new stake in Myriad Genetics during the 1st quarter worth $606,000. Hedge funds and other institutional investors own 99.02% of the company’s stock.

Analysts Set New Price Targets

MYGN has been the subject of a number of research reports. TD Cowen upped their target price on shares of Myriad Genetics from $28.00 to $30.00 and gave the company a “hold” rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. upped their price objective on Myriad Genetics from $17.00 to $20.00 and gave the company an “underweight” rating in a research note on Wednesday, August 7th. Morgan Stanley lowered their target price on Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Monday, November 18th. Wells Fargo & Company began coverage on Myriad Genetics in a research note on Tuesday, August 27th. They set an “overweight” rating and a $35.00 price target for the company. Finally, StockNews.com lowered shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $27.36.

Myriad Genetics Stock Performance

Shares of MYGN opened at $16.17 on Wednesday. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. Myriad Genetics, Inc. has a 52-week low of $14.72 and a 52-week high of $29.30. The company has a 50-day simple moving average of $22.02 and a 200-day simple moving average of $24.42. The company has a market capitalization of $1.47 billion, a PE ratio of -12.44 and a beta of 1.93.

Insiders Place Their Bets

In related news, CEO Paul J. Diaz sold 15,000 shares of the business’s stock in a transaction dated Friday, October 11th. The shares were sold at an average price of $22.93, for a total value of $343,950.00. Following the sale, the chief executive officer now directly owns 962,378 shares in the company, valued at $22,067,327.54. The trade was a 1.53 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Heinrich Dreismann sold 10,000 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $27.05, for a total transaction of $270,500.00. Following the completion of the sale, the director now directly owns 121,648 shares in the company, valued at approximately $3,290,578.40. The trade was a 7.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,012 shares of company stock worth $1,900,485. 2.10% of the stock is owned by company insiders.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.